

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.

ACTRN12614000304639

Status	TERMINATED
Phase	Phase 1
Sponsor	Achillion Pharmaceuticals, Inc
Enrollment	157 participants

Key Eligibility Criteria

Inclusion (9)

- Between 18 and 55 years old
- No clinically relevant health abnormalities
- Agree to use effective contraception (defined in the protocol)4. HCV GT-1 (Groups 9, 10, 11, 12A and 12B), HCV GT-3 (Group 12C) and HCV GT-2 (Group 12D) including all subtypes, mixed subtypes or subtypes undetermined
- Body mass index of 18 to 30 kg/m2 with a minimum body weight of 50 kg
- Aged 18 to less than 70 years old
- ... and 4 more (see full listing online)

Exclusion (12)

- History of any clinically relevant illness or clinically significant laboratory abnormalities or ECG (defined in the protocol)
- Pregnant or nursing females
- Febrile illness within 7 days of first dose of study drug
- Current Smoker
- Positive urine drug screen at day 0-1
- ... and 7 more (see full listing online)

Locations (1 total)

New Zealand